S&P 500   4,562.60 (-0.10%)
DOW   36,132.43 (+0.02%)
QQQ   387.14 (-0.04%)
AAPL   192.87 (-0.28%)
MSFT   369.12 (-0.91%)
META   319.83 (+0.48%)
GOOGL   130.77 (-0.17%)
AMZN   145.95 (-0.63%)
TSLA   246.05 (+3.07%)
NVDA   462.88 (-0.60%)
NIO   8.01 (+7.81%)
BABA   72.19 (-0.26%)
AMD   119.30 (+0.78%)
T   16.99 (-1.34%)
F   10.81 (+1.98%)
MU   73.76 (+0.09%)
CGC   0.69 (+3.36%)
GE   120.69 (+0.38%)
DIS   92.04 (+1.38%)
AMC   7.01 (-0.14%)
PFE   29.12 (+0.10%)
PYPL   60.07 (+3.71%)
XOM   98.49 (-1.94%)
S&P 500   4,562.60 (-0.10%)
DOW   36,132.43 (+0.02%)
QQQ   387.14 (-0.04%)
AAPL   192.87 (-0.28%)
MSFT   369.12 (-0.91%)
META   319.83 (+0.48%)
GOOGL   130.77 (-0.17%)
AMZN   145.95 (-0.63%)
TSLA   246.05 (+3.07%)
NVDA   462.88 (-0.60%)
NIO   8.01 (+7.81%)
BABA   72.19 (-0.26%)
AMD   119.30 (+0.78%)
T   16.99 (-1.34%)
F   10.81 (+1.98%)
MU   73.76 (+0.09%)
CGC   0.69 (+3.36%)
GE   120.69 (+0.38%)
DIS   92.04 (+1.38%)
AMC   7.01 (-0.14%)
PFE   29.12 (+0.10%)
PYPL   60.07 (+3.71%)
XOM   98.49 (-1.94%)
S&P 500   4,562.60 (-0.10%)
DOW   36,132.43 (+0.02%)
QQQ   387.14 (-0.04%)
AAPL   192.87 (-0.28%)
MSFT   369.12 (-0.91%)
META   319.83 (+0.48%)
GOOGL   130.77 (-0.17%)
AMZN   145.95 (-0.63%)
TSLA   246.05 (+3.07%)
NVDA   462.88 (-0.60%)
NIO   8.01 (+7.81%)
BABA   72.19 (-0.26%)
AMD   119.30 (+0.78%)
T   16.99 (-1.34%)
F   10.81 (+1.98%)
MU   73.76 (+0.09%)
CGC   0.69 (+3.36%)
GE   120.69 (+0.38%)
DIS   92.04 (+1.38%)
AMC   7.01 (-0.14%)
PFE   29.12 (+0.10%)
PYPL   60.07 (+3.71%)
XOM   98.49 (-1.94%)
S&P 500   4,562.60 (-0.10%)
DOW   36,132.43 (+0.02%)
QQQ   387.14 (-0.04%)
AAPL   192.87 (-0.28%)
MSFT   369.12 (-0.91%)
META   319.83 (+0.48%)
GOOGL   130.77 (-0.17%)
AMZN   145.95 (-0.63%)
TSLA   246.05 (+3.07%)
NVDA   462.88 (-0.60%)
NIO   8.01 (+7.81%)
BABA   72.19 (-0.26%)
AMD   119.30 (+0.78%)
T   16.99 (-1.34%)
F   10.81 (+1.98%)
MU   73.76 (+0.09%)
CGC   0.69 (+3.36%)
GE   120.69 (+0.38%)
DIS   92.04 (+1.38%)
AMC   7.01 (-0.14%)
PFE   29.12 (+0.10%)
PYPL   60.07 (+3.71%)
XOM   98.49 (-1.94%)

Aldeyra Therapeutics Stock Price, News & Analysis (NASDAQ:ALDX)

$3.24
+0.12 (+3.85%)
(As of 12:45 PM ET)
Compare
Today's Range
$3.05
$3.25
50-Day Range
$1.47
$6.68
52-Week Range
$1.42
$11.97
Volume
338,557 shs
Average Volume
1.35 million shs
Market Capitalization
$190.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.33

Aldeyra Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
295.3% Upside
$12.33 Price Target
Short Interest
Healthy
5.59% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.19mentions of Aldeyra Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$4.45 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.76) to ($1.08) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

540th out of 949 stocks

Pharmaceutical Preparations Industry

238th out of 421 stocks


ALDX stock logo

About Aldeyra Therapeutics Stock (NASDAQ:ALDX)

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

ALDX Stock Price History

ALDX Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Lexington biotech gets second FDA rejection this year
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
What's Going On With Aldeyra Therapeutics Stock?
Why Is Aldeyra Therapeutics (ALDX) Stock Up 40% Today?
Aldeyra (ALDX) Plummets on Dry Eye Disease Drug's Setback
See More Headlines
Receive ALDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aldeyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/27/2021
Today
12/06/2023
Next Earnings (Estimated)
12/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALDX
Employees
15
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.33
High Stock Price Target
$15.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+295.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-62,030,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.58 per share

Miscellaneous

Free Float
54,528,000
Market Cap
$183.52 million
Optionable
Optionable
Beta
1.40
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report














ALDX Stock Analysis - Frequently Asked Questions

Should I buy or sell Aldeyra Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aldeyra Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ALDX shares.
View ALDX analyst ratings
or view top-rated stocks.

What is Aldeyra Therapeutics' stock price target for 2024?

3 brokerages have issued 12-month price objectives for Aldeyra Therapeutics' stock. Their ALDX share price targets range from $8.00 to $15.00. On average, they expect the company's stock price to reach $12.33 in the next twelve months. This suggests a possible upside of 295.3% from the stock's current price.
View analysts price targets for ALDX
or view top-rated stocks among Wall Street analysts.

How have ALDX shares performed in 2023?

Aldeyra Therapeutics' stock was trading at $6.96 at the beginning of 2023. Since then, ALDX shares have decreased by 55.2% and is now trading at $3.12.
View the best growth stocks for 2023 here
.

Are investors shorting Aldeyra Therapeutics?

Aldeyra Therapeutics saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 3,160,000 shares, a decline of 5.7% from the October 31st total of 3,350,000 shares. Based on an average daily volume of 2,520,000 shares, the short-interest ratio is presently 1.3 days. Currently, 5.6% of the shares of the stock are sold short.
View Aldeyra Therapeutics' Short Interest
.

When is Aldeyra Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, December 7th 2023.
View our ALDX earnings forecast
.

How were Aldeyra Therapeutics' earnings last quarter?

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) announced its quarterly earnings data on Wednesday, October, 27th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by $0.01. During the same period in the prior year, the business posted ($0.23) earnings per share.

What ETF holds Aldeyra Therapeutics' stock ?

Invesco Dorsey Wright Healthcare Momentum ETF holds 172,465 shares of ALDX stock, representing 0.81% of its portfolio.

What other stocks do shareholders of Aldeyra Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aldeyra Therapeutics investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), KushCo (KSHB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Zosano Pharma (ZSAN), Novan (NOVN), Organigram (OGI) and Pennsylvania Real Estate Investment Trust (PEI).

Who are Aldeyra Therapeutics' major shareholders?

Aldeyra Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Laurion Capital Management LP (1.92%), Eagle Asset Management Inc. (1.77%), Deutsche Bank AG (0.50%), Deutsche Bank AG (0.50%), Rafferty Asset Management LLC (0.46%) and Ameriprise Financial Inc. (0.34%). Insiders that own company stock include Life Sciences Maste Perceptive, Martin Joseph Joyce, Perceptive Advisors Llc and Todd C Brady.
View institutional ownership trends
.

How do I buy shares of Aldeyra Therapeutics?

Shares of ALDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ALDX) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -